Loading
A phase 3 trial of Nivolumab in melanoma, run by Amgen, active and no longer recruiting.
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma is a phase 3 interventional study registered as NCT06054555 by Amgen, with 633 participants enrolled, started 2023-11-02 and due to reach its primary completion in 2028-01-25. Interventions recorded: ABP 206, Nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Amgen, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Amgen, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.